Phio Pharmaceuticals Corp. (PHIO) financial statements (2022 and earlier)

Company profile

Business Address 257 SIMARANO DRIVE
MARLBOROUGH, MA 01752
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments24,05714,2446,93414,8793,58112,90610,617
Cash and cash equivalents24,05714,2446,93414,8793,58112,9065,117
Short-term investments      5,500
Restricted cash and investments    50  
Prepaid expense     150311
Other undisclosed current assets6709203662712015050
Total current assets:24,72715,1647,30015,1503,83213,10610,978
Noncurrent Assets
Operating lease, right-of-use asset283400511
Property, plant and equipment133157210172248114163
Long-term investments and receivables     150 
Accounts and financing receivable, after allowance for credit loss     150 
Other noncurrent assets271818 182718
Total noncurrent assets:443575739172266291181
TOTAL ASSETS:25,17015,7398,03915,3224,09813,39711,159
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2,9432,0801,7731,7442,2652,5422,269
Accounts payable2837288095505119171,163
Accrued liabilities2,6601,3529641,1941,7541,6251,106
Debt  107    
Other undisclosed current liabilities125116     
Total current liabilities:3,0682,1961,8801,7442,2652,5422,269
Noncurrent Liabilities
Long-term debt and lease obligation170526411    
Long-term debt, excluding current maturities 231     
Operating lease, liability170295411
Other undisclosed noncurrent liabilities(170)(295)     
Total noncurrent liabilities:170526411    
Total liabilities:3,2382,7222,2911,7442,2652,5422,269
Stockholders' equity
Stockholders' equity attributable to parent, including:21,93213,0175,74813,5781,83310,8558,890
Common stock1112 17
Additional paid in capital138,831116,629100,56699,48780,38473,42865,988
Accumulated deficit(116,900)(103,613)(94,819)(85,911)(78,551)(66,099)(57,105)
Other undisclosed stockholders' equity attributable to parent     3,525 
Total stockholders' equity:21,93213,0175,74813,5781,83310,8558,890
TOTAL LIABILITIES AND EQUITY:25,17015,7398,03915,3224,09813,39711,159

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues  21138151934
Revenue, net  34
Gross profit:  21138151934
Operating expenses(13,511)(8,793)(9,008)(7,502)(14,077)(9,034)(10,271)
Operating loss:(13,511)(8,793)(8,987)(7,364)(14,062)(9,015)(10,237)
Nonoperating income (expense)224(1)794(11)2114
Other nonoperating income (expense)    (10)6(2)
Interest and debt expense233      
Loss from continuing operations before equity method investments, income taxes:(13,054)(8,794)(8,908)(7,360)(14,073)(8,994)(10,223)
Other undisclosed loss from continuing operations before income taxes(233)      
Loss from continuing operations before income taxes:(13,287)(8,794)(8,908)(7,360)(14,073)(8,994)(10,223)
Income tax benefit 2,6412,5322,1941,6213,6333,960
Net loss:(13,287)(6,153)(6,376)(5,166)(12,452)(5,361)(6,263)
Other undisclosed net loss attributable to parent (2,641)(2,532)(2,194) (3,633)(3,960)
Net loss attributable to parent:(13,287)(8,794)(8,908)(7,360)(12,452)(8,994)(10,223)
Preferred stock dividends and other adjustments     (2,075)(209)
Net loss available to common stockholders, diluted:(13,287)(8,794)(8,908)(7,360)(12,452)(11,069)(10,432)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(13,287)(6,153)(6,376)(5,166)(12,452)(5,361)(6,263)
Comprehensive loss, net of tax, attributable to parent:(13,287)(6,153)(6,376)(5,166)(12,452)(5,361)(6,263)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: